Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17029009 | 0.91 | NPC1 (0.43) | RAB9ANPC1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL17029010 | 0.89 | NPC1 (0.41) | RAB9ANPC1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL18364981 | 0.87 | KMO (0.44) | RAB9ANPC1MAPTHSD17B10KDM4E | |
| SCHEMBL17029016 | 0.78 | KDM4E (0.45) | RAB9ANPC1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL20344794 | 0.78 | KDM4E (0.42) | RAB9ANPC1MAPTHSD17B10KDM4E | |
| SCHEMBL17029008 | 0.76 | KMO (0.43) | RAB9ANPC1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL17029025 | 0.75 | KDM4E (0.41) | RAB9ANPC1MAPTHSD17B10KDM4E | |
| SCHEMBL17029007 | 0.74 | XPO1 (0.42) | RAB9ANPC1MAPTHSD17B10KDM4E | |
| SCHEMBL17039247 | 0.72 | KDM4E (0.40) | RAB9ANPC1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL17029026 | 0.71 | SMN1; SMN2 (0.39) | RAB9ANPC1MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | RAB9A 1173/4885NPC1 434/4885MAPT 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.